Background
ICUD-EAU (International Consultation on Urological Diseases — European Association of Urology) evidence-based guidelines on muscle-invasive and metastatic bladder cancer (MIBC), published jointly in 2012. Expert consensus document reviewing evidence for radical cystectomy, bladder preservation, perioperative chemotherapy, and palliative treatment.
Interventions and follow up
Arm A: N/A (evidence-based guideline document)
Arm B: N/A
Primary endpoint: Clinical practice recommendatio
mFollow up: N/A
Arm B: N/A
Primary endpoint: Clinical practice recommendatio
mFollow up: N/A
Results
Key Recommendations: Radical cystectomy (RC) is the standard of care for MIBC (T2–T4a, N0, M0) in surgically fit patients. Bladder-preserving trimodality therapy (TURBT + concurrent CRT) is an option for carefully selected patients unwilling or unfit for RC. Neoadjuvant cisplatin-based chemotherapy before RC improves OS and is recommended for fit patients. RT alone is inferior to concurrent CRT.
Adverse events
Main adverse events: N/A (guideline document)
Conclusions
RC remains the gold standard for MIBC, but bladder preservation is a valid alternative in selected patients (solitary lesion, complete TURBT possible, no hydronephrosis, good baseline bladder function). Neoadjuvant chemotherapy improves survival in eligible patients. Adjuvant chemotherapy data are insufficient for routine recommendation.
Key Limitations
Key Limitations: Published in 2012 — does not reflect subsequent advances including immune checkpoint inhibitors in the perioperative setting (NIAGARA, Checkmate 274) or updated neoadjuvant regimens. The evidence base for bladder preservation has strengthened with RTOG pooled analysis and randomized BC-2001 trial data published contemporaneously.
Clinical Context
The 2012 ICUD-EAU guidelines helped standardize indications for bladder preservation and neoadjuvant chemotherapy internationally. Current EAU guidelines (updated annually) continue to recommend cisplatin-based neoadjuvant chemotherapy and acknowledge bladder preservation as a curative option for selected patients.
References
References: Gakis G et al, Eur Urol 2012